@article {Zhang2020.02.25.20027953, author = {Liangsheng Zhang and Jian-Rong Yang and Zhenguo Zhang and Zhenguo Lin}, title = {Genomic variations of SARS-CoV-2 suggest multiple outbreak sources of transmission}, elocation-id = {2020.02.25.20027953}, year = {2020}, doi = {10.1101/2020.02.25.20027953}, publisher = {Cold Spring Harbor Laboratory Press}, abstract = {We examined 169 genomes of SARS-CoV-2 and found that they can be classified into two major genotypes, Type I and Type II. Type I can be further divided into Type IA and IB. Our phylogenetic analysis showed that the Type IA resembles the ancestral SARS-CoV-2 most. Type II was likely evolved from Type I and predominant in the infections. Our results suggest that Type II SARS-CoV-2 was the source of the outbreak in the Wuhan Huanan market and it was likely originated from a super-spreader. The outbreak caused by the Type I virus should have occurred somewhere else, because the patients had no direct link to the market. Furthermore, by analyzing three genomic sites that distinguish Type I and Type II strains, we found that synonymous changes at two of the three sites confer higher protein translational efficiencies in Type II strains than in Type I strains, which might explain why Type II strains are predominant, implying that Type II is more contagious (transmissible) than Type I. These findings could be valuable for the current epidemic prevention and control.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThere are no fundingAuthor DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesWe obtained 97 complete genomes of COVID-19 samples from GISAID (www.gisaid.org), NCBI and NMDC (http://nmdc.cn/$\#$/nCov/).}, URL = {https://www.medrxiv.org/content/early/2020/03/05/2020.02.25.20027953}, eprint = {https://www.medrxiv.org/content/early/2020/03/05/2020.02.25.20027953.full.pdf}, journal = {medRxiv} }